TY - JOUR
T1 - The interactive effects of verapamil and CB1cannabinoid receptor antagonist/inverse agonist, AM251 on passive avoidance learning and memory in rat
AU - Karimi, Seyed Asaad
AU - Noorbakhsh, Mariam
AU - Komaki, Hamidreza
AU - Reza Nikoo, Mohammad
AU - Hasanein, Parisa
AU - Shahidi, Siamak
AU - Faraji, Nafiseh
AU - Komaki, Alireza
N1 - Publisher Copyright:
© 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/11/29
Y1 - 2021/11/29
N2 - There are reports regarding the effects of intracellular Ca2+ and synthesis and release of endocannabinoids. The secretion of endocannabinoids depends on the L-type calcium channel. The present study evaluated the involvement of the cannabinoid CB1 receptors in the effect of L-type calcium channel blocker verapamil on passive avoidance learning (PAL) in adult male rats. In this study, we examined the effects of an acute administration of the cannabinoid CB1 receptors antagonist/inverse agonist AM251 following a chronic administration of the Ca2+ channel blocker verapamil on PAL. Male Wistar rats were administered verapamil (10, 25 and 50 mg/kg) or saline intraperitoneally (i.p) daily for 13 days (n = 10/group). After this treatment period, a learning test (acquisition) was performed, and a retrieval test was performed the following day. The results indicated that chronic systemic administration of verapamil (in a dose-dependent manner) impaired memory acquisition and retrieval. Pre-training acute administration of a selective CB1 antagonist/inverse agonist, AM251 (5 mg/kg, i.p.) did not change memory acquisition and retrieval. Co-administration of the verapamil and AM251 significantly reversed verapamil-induced amnesia, suggesting a functional interaction between AM251 and verapamil. The results indicated the interactive effects of cannabinoid CB1 receptors and L-type calcium channel in passive avoidance learning and AM251 can counter the effects of verapamil on memory.
AB - There are reports regarding the effects of intracellular Ca2+ and synthesis and release of endocannabinoids. The secretion of endocannabinoids depends on the L-type calcium channel. The present study evaluated the involvement of the cannabinoid CB1 receptors in the effect of L-type calcium channel blocker verapamil on passive avoidance learning (PAL) in adult male rats. In this study, we examined the effects of an acute administration of the cannabinoid CB1 receptors antagonist/inverse agonist AM251 following a chronic administration of the Ca2+ channel blocker verapamil on PAL. Male Wistar rats were administered verapamil (10, 25 and 50 mg/kg) or saline intraperitoneally (i.p) daily for 13 days (n = 10/group). After this treatment period, a learning test (acquisition) was performed, and a retrieval test was performed the following day. The results indicated that chronic systemic administration of verapamil (in a dose-dependent manner) impaired memory acquisition and retrieval. Pre-training acute administration of a selective CB1 antagonist/inverse agonist, AM251 (5 mg/kg, i.p.) did not change memory acquisition and retrieval. Co-administration of the verapamil and AM251 significantly reversed verapamil-induced amnesia, suggesting a functional interaction between AM251 and verapamil. The results indicated the interactive effects of cannabinoid CB1 receptors and L-type calcium channel in passive avoidance learning and AM251 can counter the effects of verapamil on memory.
KW - AM251
KW - cannabinoid CB1 receptor
KW - memory
KW - passive avoidance
KW - verapamil
KW - Endocannabinoids/pharmacology
KW - Avoidance Learning
KW - Rats, Wistar
KW - Cannabinoids/pharmacology
KW - Pyrazoles
KW - Rats
KW - Calcium/pharmacology
KW - Male
KW - Cannabinoid Receptor Agonists/pharmacology
KW - Animals
KW - Verapamil/pharmacology
KW - Piperidines
KW - Cannabinoid Receptor Antagonists/pharmacology
KW - Receptor, Cannabinoid, CB1
KW - Calcium Channels, L-Type/pharmacology
UR - http://www.scopus.com/inward/record.url?scp=85126490298&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126490298&partnerID=8YFLogxK
U2 - 10.1097/fbp.0000000000000638
DO - 10.1097/fbp.0000000000000638
M3 - Article
C2 - 34845169
AN - SCOPUS:85126490298
SN - 0955-8810
VL - 33
SP - 222
EP - 229
JO - Behavioural Pharmacology
JF - Behavioural Pharmacology
IS - 23
ER -